Abstract
Histone deacetylases (HDACs) play a central role in the epigenetic regulation of gene expression. Aberrant activity of HDACs has been found in several human cancers leading to the development of HDAC inhibitors (HDACi) as anti-tumors drugs. In fact, over the last years, a number of HDACi have been evaluated in clinical trials; these drugs have the common ability to hyperacetylate both histone and non-histone targets, resulting in a variety of effects on both cancer cells and immune responses. Clinical trials of HDACi conducted in solid tumors and hematological malignancies have shown a better clinical efficacy of these drugs in hematological malignancies. In this review, will be highlighted the mechanisms of action underlying the clinical responses obtained with these drugs and the doubts regarding the use of HDACi in cancer therapy.
Keywords: Histone deacetylases, histone deacetylases inhibitors, hematological malignancies, HDACs, epigenetic, regulation, Aberrant activity, human cancers, inhibitors, HDACi, anti-tumors, hyperacetylate, non-histone
Mini-Reviews in Medicinal Chemistry
Title: Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies
Volume: 11 Issue: 6
Author(s): A. Petrella, B. Fontanella, A. Carratu, V. Bizzarro, M. Rodriquez and L. Parente
Affiliation:
Keywords: Histone deacetylases, histone deacetylases inhibitors, hematological malignancies, HDACs, epigenetic, regulation, Aberrant activity, human cancers, inhibitors, HDACi, anti-tumors, hyperacetylate, non-histone
Abstract: Histone deacetylases (HDACs) play a central role in the epigenetic regulation of gene expression. Aberrant activity of HDACs has been found in several human cancers leading to the development of HDAC inhibitors (HDACi) as anti-tumors drugs. In fact, over the last years, a number of HDACi have been evaluated in clinical trials; these drugs have the common ability to hyperacetylate both histone and non-histone targets, resulting in a variety of effects on both cancer cells and immune responses. Clinical trials of HDACi conducted in solid tumors and hematological malignancies have shown a better clinical efficacy of these drugs in hematological malignancies. In this review, will be highlighted the mechanisms of action underlying the clinical responses obtained with these drugs and the doubts regarding the use of HDACi in cancer therapy.
Export Options
About this article
Cite this article as:
Petrella A., Fontanella B., Carratu A., Bizzarro V., Rodriquez M. and Parente L., Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies, Mini-Reviews in Medicinal Chemistry 2011; 11 (6) . https://dx.doi.org/10.2174/138955711795843347
DOI https://dx.doi.org/10.2174/138955711795843347 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets Hemophagocytic Lymphohistiocytosis (HLH): An Update
Current Immunology Reviews (Discontinued) Approaches to Optimize Gene Therapy for the Treatment of Hematologic Malignancies: Overcoming the Obstacles
Current Gene Therapy Prematurely Aged Children: Molecular Alterations Leading to Hutchinson-Gilford Progeria and Werner Syndromes
Current Aging Science In Situ Modulation of Oxidative Stress: A Novel and Efficient Strategy to Kill Cancer Cells
Current Medicinal Chemistry Stem Cell Transplantation for Hematological Malignancies: Prospects for Personalized Medicine and Co-therapy with Mesenchymal Stem Cells
Current Pharmacogenomics and Personalized Medicine Imatinib and Its Successors – How Modern Chemistry has Changed Drug Development
Current Pharmaceutical Design Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment
Current Cancer Therapy Reviews Author Index To Volume 3
Current Topics in Medicinal Chemistry Gene Therapy for Wiskott-Aldrich Syndrome
Current Gene Therapy Incidence of Profound Hypogammaglobulinemia and Infection Rate in Lymphoma Patients Following the Combination of Chemotherapy and Rituximab
Recent Patents on Anti-Cancer Drug Discovery An Innovative Fluorescent Semi-quantitative Methylation-specific PCR Method for the Determination of MGMT Promoter Methylation is Reflecting Intra-tumor Heterogeneity
Current Cancer Drug Targets Patient-derived Tumor Models for Diffuse Intrinsic Pontine Gliomas
Current Neuropharmacology A 1536-Well Fluorescence Polarization Assay to Screen for Modulators of the MUSASHI Family of RNA-Binding Proteins
Combinatorial Chemistry & High Throughput Screening Targeting Role of Glioma Stem Cells for Glioblastoma Multiforme
Current Medicinal Chemistry Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL)
Current Cancer Drug Targets Targeting the Process of Farynesylation for Therapy of Hematologic Malignancies
Current Molecular Medicine Recent Progress and Related Patents on the Applications of Bone Marrow-Derived Stem/Progenitor Cells in Regenerative Medicine and Cancer Therapies
Recent Patents on Regenerative Medicine Pleural Fluid Analysis for Evaluating Pleural Effusions
Current Respiratory Medicine Reviews Expression and Function of the Transient Receptor Potential Ion Channel Family in the Hematologic Malignancies
Current Molecular Pharmacology